For decades, oncology has chased the dream of teaching the immune system to recognize and destroy cancer cells with the same precision used against pathogens. The maturation of mRNA vaccine technology — accelerated by COVID-19 platform development — has brought that goal measurably closer, with implications for how surgeons and oncologists approach adjuvant therapy after tumor resection.
The review synthesizes design principles governing mRNA cancer vaccine construction, centering on the distinction between tumor-associated antigens (shared across patients) and tumor-specific neoantigens (unique mutations arising in an individual's cancer). Neoantigen-targeting vaccines are personalized: genomic sequencing of a patient's tumor identifies private mutations, which are then encoded into mRNA constructs capable of priming cytotoxic T-cell responses against those exact molecular signatures. Emerging clinical trial data across multiple solid tumor types suggest these constructs can generate durable antigen-specific immune activation, with the most promising signals appearing in the adjuvant setting — following surgical resection — and in minimal residual disease contexts where tumor burden is lowest.
This body of work arrives at a pivotal moment. Moderna and BioNTech have both reported early efficacy signals in melanoma and pancreatic cancer trials, with combination strategies pairing mRNA vaccines with PD-1 checkpoint inhibitors showing particular promise. The mechanistic logic is sound: vaccines prime the response; checkpoint blockade removes the brakes. The key remaining questions involve patient selection — identifying who carries sufficient neoantigen load and intact antigen-presentation machinery to respond — and manufacturing turnaround, which must compress from weeks to days for clinical viability. This review is confirmatory and directional rather than paradigm-shifting on its own, but it provides a rigorous framework that surgical oncology teams need as these platforms enter routine trial enrollment. Limitations remain substantial: most data are early-phase, cohorts are small, and no mRNA cancer vaccine has received regulatory approval as of mid-2025.